Last reviewed · How we verify
Low dose TXA
Low dose TXA, developed by Boston Children's Hospital, is a marketed drug with a key composition patent expiring in 2028. The drug's key strength lies in its established market presence and the potential for continued revenue generation until the patent expiry. The primary risk is the loss of exclusivity post-2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Low dose TXA |
|---|---|
| Also known as | Tranexamic Acid, cyclokapron,, Craniofacial surgery |
| Sponsor | Boston Children's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children (PHASE3)
- Dose-Dependent Effects of Intraoperative Tranexamic Acid on Surgical Bleeding and Transfusion Requirements in Multilevel Thoracolumbar Spinal Surgery (NA)
- Study on BT-114143 Reducing Perioperative Bleeding in Total Knee Arthroplasty（TKA） (PHASE2)
- The Perioperative Outcome of Epinephrine Infusion and Tranexamic Acid in Knee Arthroplasty Surgery (PHASE4)
- Combined IV and Topical TXA in Major Spine Surgery (EARLY_PHASE1)
- Tranexamic Acid in Vaginal Reconstructive Surgery (PHASE4)
- Acupuncture for Low-Dose Opioid for TKA Replacement (NA)
- Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose TXA CI brief — competitive landscape report
- Low dose TXA updates RSS · CI watch RSS
- Boston Children's Hospital portfolio CI